

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. – 31. (Canceled)

32. (Currently amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) in solution, wherein the at least one EDTA salt comprises at least one of tri-sodium and tetra-sodium EDTA at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is packaged in a sterile, ~~pyrogen-free~~ non-pyrogenic form.

33. (Canceled)

34. (Previously presented) A composition of either of claims 55 or 56, comprising tri-sodium and tetra-sodium EDTA.

35. – 36. (Canceled)

37. (Previously presented) A composition of any of claims 32, 56 or 57, wherein the solution comprises less than 10% (v/v) ethanol and water.

38. (Canceled)

39. (Previously presented) A composition of any of claims 32, 56 or 57, wherein the solution comprises saline.

40. (Canceled)

41. (Previously presented) A composition of any of claims 32, 55 or 57 formulated for topical application to surfaces and objects.

42. (Previously presented) A composition of any of claims 32, 55 or 57, comprising tri- and tetra-sodium EDTA salts in an aqueous solution at a concentration of between 2.0% and 8.0% (w/v) EDTA salt(s).

43. - 44. (Canceled)

45. (Previously presented) A composition provided in a dry or partially hydrated formulation that, upon reconstitution with a solution, forms an antiseptic composition of any of claims 32, 56 or 57.

46. (Previously presented) A composition of any of claims 32, 56 or 57 in a pre-filled syringe.

47. (Previously presented) A composition of any of claims 32, 56 or 57 in a single-dosage vial.

48. – 54. (Canceled)

55. (Currently Amended) An antiseptic composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) in solution, wherein the at least one EDTA salt comprises at least one of tri-sodium and tetra-sodium EDTA at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, wherein the antiseptic composition is packaged in a sterile, non-pyrogenic form, wherein the solution is water, and wherein the antiseptic composition has an osmolarity of from 240-500 mOsM/Kg.

56. (Currently amended) A lock flush composition comprising at least one salt of ethylene diamine tetraacetic acid (EDTA) in solution, wherein the at least one

EDTA salt comprises at least one of tri-sodium and tetra-sodium EDTA at a concentration of at least 2.0% (w/v) and less than 15% (w/v), wherein the lock flush composition has a pH of at least 9.5, wherein the lock flush composition is packaged in a sterile, ~~pyrogen-free~~ non-pyrogenic form, and wherein the lock flush composition is biocompatible for use in in-dwelling access catheters, urinary catheters, nasal tubes and throat tubes.

57. (Currently amended) An antiseptic composition comprising tri-sodium and tetra-sodium ethylene diamine tetraacetic acid (EDTA) in solution at a concentration of ~~at least 2.0% (w/v) and less than 15% (w/v)~~ sufficient to have antimicrobial activity, wherein the antiseptic composition has a bactericidal effect over a broad spectrum of microbes, wherein the antiseptic composition has a pH of at least 9.5, and wherein the antiseptic composition is packaged in a sterile, ~~pyrogen-free~~ non-pyrogenic form.

58. (New) A composition of any of claims 32, 55 or 56, wherein the EDTA salt provides at least 50% of a total antimicrobial activity of the composition.

59. (New) A composition according to claim 57, wherein the combination of tri-sodium and tetra-sodium EDTA provides at least 50% of a total antimicrobial activity of the composition.

60. (New) A composition according to claim 57, wherein the concentration of tri-sodium and tetra-sodium EDTA in solution is at least 2.0% (w/v) and less than 15% (w/v).